http://qstzone.com/content/arkansas-health-department-sponsors-amateur-radio-training
GenVec, Inc. (Nasdaq: GNVC) is a clinical stagwe biopharmaceutical company developing and working to commercializeinnovative gene-based therapeutics to treat serious and life-threatening disease, including cancer, heart disease and diseasexs of the eye. We have four product candidates in clinical developmentas follows: - TNFerade is our lead product candidate, a novel therapy with a unique mechanism of actionn for use by multi-disciplinary oncology currently in Phase 2 trials in locally advance d pancreatic cancer, non-metastic esophageal cancedr and rectal cancer.
- BioBYPASS Positive data presented from a controlled Phase 2 study in 71 patients with severd heart disease and notreatmenf options. We expect to beginn a randomized, placebo-controlled Phase 2B trial with our Cordis Corporation, in the fourthb quarter of 2004 to study the clinical benefitt of BIOBYPASS delivered by the NOGASTAR mapping and Myostar injection cathetee system. - AdPEDF Patient enrollmen completed in a dose escalation Phase 1 triaol for the treatment ofwet age-related macular degenerationb (AMD), a leading cause of blindnesds in individuals over the age of 50. - Cell Transplantation Therapy for congestiveheart failure.
Each of our product candidatezs (excluding Cell Transplantation Therapy) were discovere d using our patent-protected gene delivery technologyu platform to deliver genes that produce medicallu beneficial proteins at the siteof ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment